Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss frontline treatment selection in EGFR-mutated NSCLC.
Back
Traversing Frontline Treatment Decisions in EGFR-Mutated Non–Small Cell Lung Cancer
Luis Raez, MD, FACP, FCCP, and Alexander I Spira MD, PhD, FACP, FASCO, share evolving treatment considerations in EGFR-mutated NSCLC.
Traversing Frontline Treatment Decisions in EGFR-Mutated Non–Small Cell Lung Cancer
Episodes
All
All
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss how NCCN Guidelines can influence treatment decisions in EGFR-mutated NSCLC.
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss trial data informing amivantamab use in EGFR-mutated NSCLC.
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss the significance of the FDA approval of subcutaneous amivantamab in EGFR-mutated NSCLC.
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss safety and toxicity management in EGFR-mutated NSCLC.
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss ongoing research in EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5